FDA — authorised 8 October 2002
- Application: NDA020732
- Marketing authorisation holder: INDIVIOR
- Local brand name: SUBUTEX
- Indication: TABLET — SUBLINGUAL
- Status: approved
FDA authorised SL Buprenorphine on 8 October 2002
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 8 October 2002; FDA has authorised it.
INDIVIOR holds the US marketing authorisation.